Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752774 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
A Phase 1 study of Spasticity, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT04752774 is a Phase 1 study of Spasticity that is actively recruiting participants, run by Ipsen. The registered enrollment target is 240 participants, above the 62-participant average among 8 other Spasticity trials with a reported enrollment target (287% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT04752774, a Phase 1 study of Spasticity, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL IPN10200
- BIOLOGICAL Dysport
Study Locations (20)
Other
- Medical University Innsbruck, Department of Neurology - Innsbruck
- Kepler University Hospital GmbH, Department of Neurology and Psychiatry - Linz
- Brothers of Charity Hospital Linz, Department of Neurology I - Linz
- Medical University Vienna, Department of Neurology - Vienna
- Multiprofile Hospital for Active Treatment "Heart and Brain" - Pleven
- Medical Center "Rusemed" EOOD - Rousse
- Multiprofile Hospital for Active Treatment of Neurology and Psychiatry "Sveti Naum", Sofia, Neurological Diseases Clinic for Neurodegenerative and Peripheral Neurological Diseases - Sofia
- Diagnostic Consulting Center - Convex EOOD - Sofia
- Medical Center Medica Plus Ltd - Veliko Tarnovo
- University Hospital Hradec Kralove, Clinic of Neurology - Hradec Králové
- Hospital Jihlava, Department of Neurology - Jihlava
- University Hospital Ostrava, Clinic of Neurology, Center for Demyelinating diseases - Ostrava
- Regional Hospital Pardubice, Clinic of Neurology - Pardubice
- University Hospital Kralovske Vinohrady, Clinic of Neurology - Prague
- General University Hospital in Prague, Clinic of Neurology - Prague
California
- Rancho Los Amigos National Rehab - Downey
Kansas
- Kansas Institute of Research - Overland Park
Michigan
- Quest Research Institute - Farmington Hills
Pennsylvania
- Einstein Physical Medicine and Rehabilitation at Elkins Park - Elkins Park
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752774
The ClinicalTrials.gov registry entry for NCT04752774 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 8 other Spasticity trials with a reported enrollment target (287% higher). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spasticity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04752774 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT04752774 about?
NCT04752774 is a clinical study titled "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.". The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper lim...
What is the current status of trial NCT04752774?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2021-04-29. Estimated completion is 2027-10-30.
What conditions does trial NCT04752774 study?
This clinical trial studies the following conditions: Spasticity.
What interventions are being tested in trial NCT04752774?
The interventions under investigation include: Placebo (DRUG), IPN10200 (BIOLOGICAL), Dysport (BIOLOGICAL).
Who is sponsoring clinical trial NCT04752774?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752774 being conducted?
This trial has 20 study locations across California, Kansas, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spasticity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dry Needling in Multiple Sclerosis
RECRUITING · NA
-
Leg Stretching Using an Exoskeleton on Demand for People With Spasticity
RECRUITING · NA
-
Spinal Cord Stimulation to Augment Activity Based Therapy
COMPLETED · NA
-
Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
COMPLETED · NA
-
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
COMPLETED · Phase 4
-
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.